Effect of bortezomib on the efficiency of hematopoietic stem cell mobilization in patients with multiple myeloma

  • Authors: Pokrovskaia OS1, Mendeleeva LP1, Urnova ES1, Gaponova TV1, Gal'tseva IV1, Kuz'mina LA1, Akhundova FM1, Kalinin NN1, Gretsov EM1, Parovichnikova EN1, Savchenko VG1
  • Affiliations:
  • Issue: Vol 84, No 7 (2012)
  • Pages: 35-41
  • Section: Articles
  • URL: https://ter-arkhiv.ru/0040-3660/article/view/31058
  • Cite item


Aim. To study the results of mobilizing and collecting autologous hematopoietic stem cells (HSC) in patients with multiple myeloma (MM) receiving bortezomib as part of induction therapy regimens. Materials and methods. In June 2001 to April 2010, the Department of Bone Marrow Transplantation, Hematology Research Center, Ministry of Health and Social Development of Russia, mobilized autologous HSC in 93 patients with MM, by using cyclophosphan (CF) and granulocyte colony-stimulating factor. The analysis covered 73 patients who received VAD and/or bortezomib-containing courses as induction therapy. Group 1 comprised 30 patients whose induction therapy was performed as 3-4 courses of VAD. Group 2 included 19 patients who had 2-4 courses of PAD or 4-8 courses of bortezomib + dexamethasone in addition to 1-3 courses of VAD. Group 3 combined 24 patients who used 6-8 courses of bortezomib + dexamethasone or 3-4 courses of PAD + 4-6 courses of bortezomib + dexamethasone. Results. In Group 1 patients whose induction therapy was performed as 3-4 courses of VAD, baseline peripheral blood CD34+ cell counts were 3,575±631 in 1 ml, which was statistically significantly higher than those in Group 2 patients who had bortezomib-containing courses in addition to VAD courses. In Group 2 patients, premobilization CD34+ cell counts were 2,164±516 in 1 ml. The lowest blood CD34+ cell levels (1,586±405 in 1 ml) were observed in Group 3 patients in whom bortezomib was used as first-line therapy. In Group 1 patients, the maximum peripheral blood counts of CD34+ cells were 322,287±73,994 in 1 ml, which was significantly higher than their maximum level in Groups 2 (231,624±39,708 in 1 ml) and 3 (161,007±44,266 in 1 ml) patients. The efficiency of mobilization proved to be high; more than 4.0·106/kg of CD34+ cells were collected in all the patients with bortezomib-containing induction therapy, which allowed two autologous HSC transplantations to be carried out.Conclusion. Adding bortezomib at the stage of induction has no significant impact on the results of HSC mobilization and collection. By taking into account the possibility of achieving a complete or very good partial response in 40-60% of the patients using the bortezomib-containing regimens as first-line therapy, bortezomib should be considered as an essential drug as part of induction therapy.

Full Text

Restricted Access

About the authors

O S Pokrovskaia

Email: pokrovskaya.o.s@yandex.ru

L P Mendeleeva

Email: mlp@blood.ru

E S Urnova

Email: eurnova@mail.ru

T V Gaponova

Email: gaponova.tatj@yandex.ru

I V Gal'tseva

Email: irag@blood.ru

L A Kuz'mina

Email: kuzlara@rambler.ru

F M Akhundova

Email: rf_fina@hotmail.com

N N Kalinin

Email: kalininn@blood.ru

E M Gretsov

E N Parovichnikova

Email: elenap@blood.ru

V G Savchenko

Email: svg@blood.ru


  1. Child J.A., Morgan G.J., Davies F.E. et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
  2. Attal M., Harousseau J.L., Stoppa A.M. et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
  3. O'Shea D., Giles C., Terpos E. et al. Predictive factors for survival in myeloma patients who undergo autologous stem cell transplantation: a single-centre experience in 211 patients. Bone Marrow Transplant 2006; 37: 731-737.
  4. Dingli D., Pacheco J.M., Dispenzieri A. et al. Serum M-spike and transplant outcome in patients with multiple myeloma. Cancer Sci 2007; 98: 1035-1040.
  5. Barlogie B., Kyle R.A., Anderson K.C. et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936.
  6. Blade J., Rosinol L., Sureda A. et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755-3759.
  7. Fermand J.P., Katsahian S., Divine M. et al. Highdose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227-9233.
  8. Fermand J.P., Ravaud P., Chevret S. et al. Highdose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
  9. Palumbo A., Bringhen S., Petrucci M.T. et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood 2004; 104: 3052-3057.
  10. Kumar S.K., Rajkumar S.V., Dispenzieri A. et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008; 111: 2516-2520.
  11. Baldomero H., Gratwohl M., Gratwohl A. et al. The EBMT activity survey 2009: trends over the past 5 years. Bone Marrow Transplant 2011; 46 (4): 485-501.
  12. Менделеева Л.П., Митиш Н.Е., Клясова Г.А. и др. Инфекционные осложнения после трансплантации аутологичных гемопоэтических клеток при гемобластозах. Тер арх 2005; 7: 33-39.
  13. Менделеева Л.П., Савченко В.Г., Павлова О.А. и др. Мобилизация гранулоцитарным колониестимулирующим фактором аутологичных гемопоэтических клеток крови у больных лимфомами и раком молочной железы. Пробл гематол 1999; 4: 5-12.
  14. Siena S., Schiavo R., Pedrazzoli P. et al. Therapeutic relevance of CD34 cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
  15. Sola C., Maroto P., Salazar R. et аl. Bone marrow transplantation: prognostic factors of peripheral blood stem cell mobilization with cyclophospamide and filgrastim (r-metHuG-CSF): the CD34+cell dose positively affects the time of hematopoietic recovery and supportive requirements after high-dose chemotherapy. Hematology 1999; 4: 195-209.
  16. Gordan L.N., Sugrue M.W., Lynch J.W. et al. Poor mobilization of peripheral blood stem cells is a risk factor for worse outcome in lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2003; 44: 815-820.
  17. Toor A.A., Ayers J., Strupeck J. et al. Favourable results with a single autologous stem cell transplant following conditioning with busulphan and cyclophosphamide in patients with multiple myeloma. Br J Haematol 2004; 124: 769-776.
  18. Cottler-Fox M.H., Lapidot T., Petit I. et al. Stem cell mobilization. In 45-th Annual Meeting of American Society of Hematology. Educ. Program Book: San-Diego; 2003; Hematology 2003 (1): 419-437.
  19. Kuittinen T., Nousiainen T., Halonen P. et al. Prediction of mobilization failure in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2004; 33: 907-912.
  20. Покровская О.С., Менделеева Л.П., Урнова Е.С. и др. Оптимизация режимов мобилизации гемопоэтических стволовых клеток у больных с множественной миеломой. Тер арх 2011; 7: 50-57.
  21. Attal M., Harousseau J.L., Facon T. et al. Single versus double autologous stem cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
  22. Fermand J.P., Ravaud P., Katsahian S. et al. High dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients 55 to 65 years of age. Blood 1999; 94: Suppl 1: 396.
  23. Tribalto M., Amadori S., Cudillo L. et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian multicenter study. Haematologica 2000; 85: 52-58.
  24. Kyle R.A., Rajkumar V. Multiple myeloma. N Engl J Med 2004; 351: 1860-1873.
  25. Richardson P.G., Barlogie B., Berenson J. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-2617.
  26. Jagannath S., Barlogie B., Berenson J. et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127: 165-172.
  27. Fitzgerald M., Fraser C., Webb I. et al. Normal hematopoietic stem cell function in mice following treatment with bortezomib. Biol Blood Marrow Transpl 2003; 9: 193.
  28. Lonial S., Waller E.K., Richardson P.G. et al. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005; 106 (12): 3777-3784.
  29. Harousseau J.L., Mathiot C., Attal M. et al. Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantion (ASCT) in previously untreated multiple myeloma (MM): updated data from IFM 2005/01 trial [abstract]. J Clin Oncol 2008; 26: 8505.
  30. Sonneveld P., van der Holt B., Schmidt-Wolf I.G.H. et al. First analysis of HOVON-65/GMMG-HD4 randomized phase iii trial comparing bortezomib, adriamycine, dexamethasone (PAD) vs VAD as induction treatment prior to high dose melphalan (HDM) in patients with newly diagnosed multiple myeloma (MM) [abstract]. Blood 2008; 112: 653.
  31. Oakervee H., Popat R., Cavenagh J.D. Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment. Leuk Lymphoma 2007; 48 (10): 1910-1921.
  32. Pokrovskaya O., Mendeleeva L., Alexeeva I. et al. Treatment of multiple myeloma with autologous stem cell transplantation: a long-term observation. Bone Marrow Transplant 2011; 46: Suppl 1: P906 [abstract].
  33. Поспелова Т.И, Скворцова Н.В., Нечунаева И.Н. Результаты лечения множественной миеломы препаратом бортезомиб. Онкогематол 2009; 2: 35-41.
  34. Бессмельцев С.С., Стельмашенко Л.В., Подольцева Э.И. и др. Бортезомиб (велкейд) в комбинации с дексаметазоном при рецидиве и рефрактерных формах множественной миеломы. Онкогематол 2007; 4: 61-66.
  35. Вотякова О.М. Современная терапия множественной миеломы. Бюл сибирской мед 2008; Приложение 3: 33-41.
  36. Лучинин А.С., Загоскина Т.П. Эффективность применения комбинации бортезомиба, мелфалана и преднизолона при множественной миеломе. Гематол и трансфузиол 2009; 4: 9-13.
  37. The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121 (5): 749-757.
  38. Durie B.G.M., Harousseau J.L., Miguel J.S. et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20 (9): 1467-1473.
  39. Harousseau J.L., Attal M., Leleu X. et al. Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006; 91: 1498-1505.
  40. Harousseau J.L., Marit G., Caillot D. et al. VELCADE/dexamethasone (Vel/Dex) versus VAD as induction treatment prior to autologous stem cell transplantation (ASCT) in newly diagnosed multiple myeloma (MM): an interim analysis of the IFM 2005-01 randomized multicenter phase III trial. Blood 2006; 108: 21a.
  41. Barlogie B., Anaissie E., van Rhee F. et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol 2007; 138: 176-185.
  42. Oakervee H., Popat R., Curry N. et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755-762.
  43. Van de Velde H.J.K., Liu X., Chen G. et al. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007; 92: 1399-1406.
  44. Lahuerta J.J., Mateos M.V., Martinez-Lopez J. et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775-5782.



Abstract - 30



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:


© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies